17-3688044-C-T
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3_Strong
The NM_002561.4(P2RX5):c.949G>A(p.Gly317Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000312 in 1,604,038 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0000067 ( 0 hom., cov: 28)
Exomes 𝑓: 0.0000027 ( 0 hom. )
Consequence
P2RX5
NM_002561.4 missense
NM_002561.4 missense
Scores
7
9
3
Clinical Significance
Conservation
PhyloP100: 7.53
Genes affected
P2RX5 (HGNC:8536): (purinergic receptor P2X 5) The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the neighboring downstream gene, TAX1BP3 (Tax1 binding protein 3). [provided by RefSeq, Mar 2011]
P2RX5-TAX1BP3 (HGNC:49191): (P2RX5-TAX1BP3 readthrough (NMD candidate)) This locus represents naturally occurring read-through transcription between the neighboring P2RX5 (purinergic receptor P2X, ligand-gated ion channel, 5) and TAX1BP3 (Tax1 binding protein 3) genes on chromosome 17. The read-through transcript is a candidate for nonsense-mediated mRNA decay (NMD), and is thus unlikely to produce a protein product. [provided by RefSeq, Mar 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.984
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
P2RX5 | NM_002561.4 | c.949G>A | p.Gly317Arg | missense_variant | 9/12 | ENST00000225328.10 | NP_002552.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
P2RX5 | ENST00000225328.10 | c.949G>A | p.Gly317Arg | missense_variant | 9/12 | 1 | NM_002561.4 | ENSP00000225328.5 | ||
P2RX5 | ENST00000697413.1 | c.949G>A | p.Gly317Arg | missense_variant | 9/13 | ENSP00000513301.1 | ||||
P2RX5-TAX1BP3 | ENST00000550383.1 | n.949G>A | non_coding_transcript_exon_variant | 9/15 | 2 | ENSP00000455681.1 |
Frequencies
GnomAD3 genomes AF: 0.00000672 AC: 1AN: 148834Hom.: 0 Cov.: 28
GnomAD3 genomes
AF:
AC:
1
AN:
148834
Hom.:
Cov.:
28
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000275 AC: 4AN: 1455204Hom.: 0 Cov.: 30 AF XY: 0.00000276 AC XY: 2AN XY: 723578
GnomAD4 exome
AF:
AC:
4
AN:
1455204
Hom.:
Cov.:
30
AF XY:
AC XY:
2
AN XY:
723578
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000672 AC: 1AN: 148834Hom.: 0 Cov.: 28 AF XY: 0.0000138 AC XY: 1AN XY: 72502
GnomAD4 genome
AF:
AC:
1
AN:
148834
Hom.:
Cov.:
28
AF XY:
AC XY:
1
AN XY:
72502
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 05, 2023 | The c.949G>A (p.G317R) alteration is located in exon 9 (coding exon 9) of the P2RX5 gene. This alteration results from a G to A substitution at nucleotide position 949, causing the glycine (G) at amino acid position 317 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Benign
.;.;.;T;.;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D
M_CAP
Benign
D
MetaRNN
Pathogenic
D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
.;.;.;H;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
.;D;D;D;D;D
REVEL
Uncertain
Sift
Uncertain
.;D;D;D;D;D
Sift4G
Pathogenic
D;D;D;D;D;D
Polyphen
0.99, 1.0, 0.99
.;D;D;D;.;D
Vest4
MutPred
0.93
.;.;.;Gain of MoRF binding (P = 0.0086);.;.;
MVP
MPC
0.65
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at